Behavior: Smoking, Quitting and Genetics

IN THIS ARTICLE

Nicotine addiction

Old drugs

New Drugs

The Doctor's Health Tip Problems swallowing solid food and weight loss may be a sign of cancer of the esophagus. more...

OTHER TOPICS

Stress

Rewards/addictions

Women smokers

The End of Stress, Dr. McEwen's new book

The End of Stress, now available at amazon.com

Smoking, Quitting and Genetics

Eric Siu, M.Sc., Nael Al Koudsi, H.B.Sc., Man Ki Ho, H.B.Sc., Rachel F. Tyndale, M.Sc., Ph.D.

Dr. Tyndale is a Scientist at the Centre for Addiction and Mental Health and a Professor of Pharmacology, University of Toronto. Mr. Siu, Mr. Al Koudsi, and Miss Ho are doctoral students in the Department of Pharmacology at the University of Toronto.

Protective Factors
Recent decades have witnessed a revolution in public awareness about the dangers of smoking cigarettes, especially in the United States and most other developed nations. The number of smokers in those countries has plummeted. Largely because smoking is highly addictive, however, it remains a major, worldwide health threat.

According to the World Health Organization, smoking is currently responsible for the death of approximately 5 million people each year.¹ If current trends continue, by the year 2030 an estimated that 10 million people will die each year because of smoking.² In the United States alone, tobacco use today accounts for approximately $157 billion annually in health care costs and lost economic productivity.³

Depite increasingly tough anti-smoking laws and policies, as well as heightened awareness of the negative health effects of cigarette smoking, approximately 21% of adults in the United States smoke.^4,5 A key national health objective of the U.S. is to lower the number of adults who smoke to below 12% by the year 2010; and while there has been an overall decline in recent years, it does not appear that this goal will be met.⁶

Smoking habits vary tremendously among American racial and ethnic groups, with American Indians/Alaska Natives having the highest rates at 33.4%, followed by non-Hispanic whites (22.2%) and non-Hispanic blacks (20.2%), and the lowest rates found among Hispanics (15.0%) and Asians (11.3%). The gender gap in smoking prevalence has dramatically narrowed in recent years, with overall current rates of 23.4% in men and 18.5% in women (Figure 1).

It is obvious that the development of better treatments for smoking addiction would have a massive health benefit. Research has given us greater understanding of the exact mechanisms of nicotine addiction within the human body, especially the role genes play.

Figure 1. The Change in Smoking Prevalence in Men and Women From 1955 to 2005.*

* Cokkinides, V. et al. Progress and opportunities in tobacco control. CA Cancer J Clin 2006;56(3):135-142.

Nicotine on the Brain
While as many as 80% of smokers say they want to quit smoking, only a small fraction -- less than 5% -- are actually able to get off cigarettes and stay off. This is mainly because inhaled nicotine, the main psychoactive ingredient in cigarettes, is powerfully addictive.^7,8 Cigarettes, unlike other nicotine delivery systems (e.g., patch or gum), are particularly addictive because smoked nicotine is absorbed and reaches the brain quickly, within 10-20 seconds.⁹ Rapid delivery intensifies addictiveness by closely associating the behavior (smoking) and the reward (the pleasurable effect of nicotine on the brain).

Once it reaches the brain, nicotine causes mood elevation, decreased anxiety, decreased appetite, increased arousal and cognitive enhancement, by stimulating a part of the central nervous system called nicotinic acetylcholine receptors (nAChRs).^{10,11,12,13,14,15,16}

The main mechanism by which nicotine is thought to create addiction is by releasing a natural substance, dopamine, found in the brain. Dopamine has many functions in the brain. Most importantly, it is central to the reward/pleasure system, providing feelings of enjoyment as positive reinforcement to motivate us to perform certain activities.

Dopamine can be released by experiences such as eating, sex and the use of certain drugs.^17,18 Nicotine also causes the release of other substances, called neurotransmitters, for example, serotonin and GABA. Serotonin helps regulate mood, sleep, sexuality and appetite and can indirectly cause dopamine release.¹⁹

The Genetics of Nicotine Addiction
Cigarette smoking is a complex behavior that involves a number of stages such as initiation, experimentation, regular use, dependence, quitting and relapse.^20,21 While factors such as the influence of family members, peers and culture undoubtedly affect smoking behavior, genetics also plays a role.

Twin studies have been used to determine whether complex traits such as smoking can be inherited and to what degree. This is known in genetics as "heritability," and it is expressed as a percentage. In other words, 0% heritability would mean that the risk for a particular behavior is the result of environmental influences; and 100% heritability would mean that the risk is essentially entirely from traits inherited from one's parents.²²

Based on numerous twin studies, the heritability for risk for trying smoking at all has been estimated in the range of 11-78%.^{23,24,25,26,27,28,29,30,31} Once smoking is initiated, the heritability for regular smoking has been estimated at 28-84%,(32), for number of cigarettes smoked per day at 45-86%^{33,34,35,37,38,39} and for dependence on nicotine at 31-75%.⁴⁰) A genetic influence on nicotine withdrawal symptoms and ability to quit has also been identified, with heritability estimated at 26-48% and 50-58%, respectively.^41,42,43 Taken together, these studies suggest that genetics plays a large role in most aspects of smoking.

Advances in our understanding of the human genome have even allowed scientists to identify some of the specific genes involved in smoking.^44,45,46 Nicotine's addictive properties are a result of the activation of the special receptors (nAChRs) in the brain and the impact this has on certain neurotransmitter systems (e.g., dopamine, serotonin and GABA). Genes that relate to the actions of these neurotransmitters, therefore, are the focus of researchers.^47,48

Dopaminergic System
The dopaminergic system, the part of the central nervous system that produces and regulates dopamine, has been studied extensively because of its pivotal role in nicotine dependence. Researchers have been able to pinpoint specific variations in specific genes that seem to affect smoking behavior.^{49,50,52,53,54,55,56,57,58,59} Some studies have even been able to suggest which anti-smoking therapies will be more effective for a particular individual.^{60,61,62,63,64,65,66,67,68,69,70,71}

Nicotinic Receptors
A recent study found an association between genetic variations in the brain nicotinic receptors with smoking quantity and heaviness of nicotine dependence.^72,73,7475

Other Candidate Genes
The serotonin and the opioid systems, both parts of the central nervous system, also play a role in nicotine dependence.^76,77 Not surprisingly, associations have been reported between genetic variants in serotonin or opioid receptors and various smoking behaviors and quitting rates.^78,79,80

The Promise of Genetic Association Studies
Gene association studies are providing insight into the neurobiological mechanisms of nicotine dependence and may, in the future, allow geneticists to identify individuals who are at a greater risk for smoking or smoking related illnesses. In addition, this research holds the promise of improving smoking addiction treatments by matching the type, dosage and duration of treatment to an individual's genetic profile.

Established Drug Treatments

Nicotine Replacement Therapies
Nicotine replacement products (NRTs) were one of the first treatments for nicotine dependence approved by the U.S. Federal Drug Administration (FDA). Today, there are several NRTs on the market, including gum, transdermal patch, vapor inhaler, nasal spray, lozenge and sublingual tablet. NRT treatments help people quit by delivering nicotine without the exposure to cancer-causing chemicals found in cigarette smoke. NRTs maintain the desirable emotional states (e.g., elevated mood, increased attention) achieved from smoking and avoid unpleasant withdrawal symptoms.^81,8283,84 Overall, NRTs have been fairly effective in helping smokers quit.84⁸⁴ No one type of NRT appears to be generally more effective than the others.^85,86,87

Bupropion (Zyban^®)
Smoking and depression are linked in ways we do not yet fully understand. Certainly, both are influenced by dopamine levels in the brain.^88,89 The first non-nicotine product to be used to help people quit smoking was the anti-depressant bupropion. Bupropion appears to work by reducing craving and by alleviating withdrawal symptoms; however, other less well understood mechanisms may also be involved.^{90,91,92,93,94,96,97,98,99,100,101,102,103}

Most -- but not all -- studies have demonstrated bupropion to be effective at helping smokers quit.^{104,105,106,107,108,,110,111,112,113,114} As for safety, the drug causes few serious side effects, the most common being insomnia; nausea and vomiting; and dizziness.¹¹⁵

Drugs Now in Development

Varenicline (Chantix^TM)
Varenicline has recently been approved by the FDA to help people quit smoking.¹¹⁶ Varenicline seems to reduce nicotine reward during smoking and to stimulate dopamine release to reduce craving and withdrawal symptoms.¹¹⁷ Two separate studies found that varenicline more than doubled successful quitting rates after one year. Varenicline was also found to be significantly better at helping people stay off cigarettes than bupropion. The most common side effect of varenicline is nausea.^118,119

Nicotine Vaccines
Nicotine vaccines represent a new approach. The principle is to stimulate the body's production of antibodies which will prevent nicotine from entering the brain.^120,121 One advantage of nicotine vaccines is that daily medication is not required. Two recent studies found that nicotine vaccines may be safe and effective. Further study will be needed, however, because of the small numbers of subjects in both studies. Most reported side effects were mild to moderate and were taken care of without medical treatment.^122,123

Rimonabant (SR141716)
Rimonabant prevents the release of dopamine in response to nicotine.¹²⁴ Several studies have been done using this drug, with mixed results.^125,126 The most common side effects were nausea and upper respiratory tract infection. Rimonabant has not yet been approved for use in the USA.

Metabolism Modulators
Another novel approach to helping people quit smoking would to administer drugs which prevent the body from metabolizing nicotine. They are currently under study.^{127,128,129,130,131,132,133,134,136,137,138,139,140}

Summary
Cigarettes are dangerous not because they contain nicotine but because of the variety of cancer-causing chemicals contained in cigarette smoke. Nicotine, however, is what makes cigarette smoking addictive. Like other abused drugs such as cocaine, nicotine acts on the central nervous system to stimulate feelings of pleasure and reward. Genetic studies have identified a host of genes that may contribute to an individual's risk of becoming addicted to tobacco, the strength of the addiction and the difficulty of quitting.

Current drug treatments for tobacco dependence include nicotine replacement therapies (NRTs), bupropion (Zyban^®) and the newly approved varenicline (Chantix^TM). Ongoing genetic studies, however, are likely to provide new classes of drugs and more effective treatments to help people quit smoking.

October 2006

Email this article to a friend

References
1. Why is tobacco a public health priority? 2006. In World Health Organization: Tobacco Free Initiative. return

2. The World Bank. 1999. Curbing the Epidemic:Governments and the Economics of Tobacco Control. Washington DC: The World Bank. return

3. Centers for Disease Control and Prevention. 2002. Annual Smoking-Attributable Mortality, Years of Potential Life Lost, and Economic Costs --- United States, 1995--1999. Morbidity and Mortality Weekly Report 51: 300-3. return

4. Centers for Disease Control and Prevention. 2005. Cigarette Smoking Among Adults: United States, 2004. In Morbidity and Mortality Weekly Report, pp. 1121-48. return

5. Cokkinides V, Bandi P, Ward E, Jemal A, Thun M. 2006. Progress and Opportunities in Tobacco Control. CA Cancer J Clin 56: 135-42. return

6. U.S. Department of Health and Human Services. 2000. Healthy People 2010, 2nd ed. With Understanding and Improving Health and Objectives for Improving Health (2 vols.). ed. DC Washington. return

7. Diagnostic and Statistical Manual - Text Revision IV. 2000. American Psychiatric Associations. return

8. Baillie AJ, Mattick RP, Hall W. 1995. Quitting smoking: estimation by meta-analysis of the rate of unaided smoking cessation. Aust J Public Health. 19: 129-31. return

9. Benowitz NL. 1988. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N Engl J Med 319: 1318-30. return

10. Picciotto MR. 2003. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci 24: 493-9. return

11. Laviolette SR, van der Kooy D. 2004. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci 5: 55-65. return

12. Wonnacott S, Sidhpura N, Balfour DJ. 2005. Nicotine: from molecular mechanisms to behaviour. Curr Opin Pharmacol 5: 53-9. return

13. Mathieu-Kia AM, Kellogg SH, Butelman ER, Kreek MJ. 2002. Nicotine addiction: insights from recent animal studies. Psychopharmacology (Berl) 162: 102-18. return

14. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, et al. 2004. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 306: 1029-32. return

15. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, et al. 1998. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391: 173-7. return

16. Besson M, David V, Suarez S, Cormier A, Cazala P, et al. 2006. Genetic dissociation of two behaviors associated with nicotine addiction: Beta-2 containing nicotinic receptors are involved in nicotine reinforcement but not in withdrawal syndrome. Psychopharmacology (Berl) 187: 189-99. return

17. Balfour DJ. 2004. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. Nicotine Tob Res 6: 899-912. return

18. Pidoplichko VI, Noguchi J, Areola OO, Liang Y, Peterson J, et al. 2004. Nicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotine addiction. Learn Mem 11: 60-9. return

19. Seth P, Cheeta S, Tucci S, File SE. 2002. Nicotinic--serotonergic interactions in brain and behaviour. Pharmacol Biochem Behav 71: 795-805. return

20. Malaiyandi V, Sellers EM, Tyndale RF. 2005. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clinical Pharmacology & Therapeutics 77: 145. return

21. Mayhew KP, Flay BR, Mott JA. 2000. Stages in the development of adolescent smoking. Drug and Alcohol Dependence 59: 61. return

22. Winerman L. 2004. A second look at twin studies. Monitor on Psychology 35: 46. return

23. True WR, Heath AC, Scherrer JF, Waterman B, Goldberg J, et al. 1997. Genetic and environmental contributions to smoking. Addiction 92: 1277-88. return

24. Heath AC, Martin NG. 2003. Genetic models for the natural history of smoking: evidence for a genetic influence on smoking persistence. Addictive Behaviors 18: 19-34. return

25. Kendler KS, Neale MC, Sullivan P, Corey LA, Gardner CO, Prescott CA. 1999. A population-based twin study in women of smoking initiation and nicotine dependence. Psychol Med 29: 299-308. return

26. Heath AC, Cates, R., Martin, N. G., Meyer, J., Hewitt, J. K., Neale, M. C. & Eaves, L. J. 1993. Genetic contribution to risk of smoking initiation: comparisons across birth cohorts and across cultures. Journal of Substance Abuse 5: 221-46. return

27. Madden PAF, Heath AC, Pedersen NL, Kaprio J, Koskenvuo MJ, Martin NG. 1999. The Genetics of Smoking Persistence in Men and Women: A Multicultural Study. Behavior Genetics 29: 423. return

28. Maes HH, Sullivan PF, Bulik CM, Neale MC, Prescott CA, et al. 2004. A twin study of genetic and environmental influences on tobacco initiation, regular tobacco use and nicotine dependence. Psychol Med 34: 1251-61. return

29. Sullivan PF, Kendler KS. 1999. The genetic epidemiology of smoking. Nicotine & Tobacco Research 1. return

30. Vink JM, Willemsen G, Boomsma DI. 2005. Heritability of Smoking Initiation and Nicotine Dependence. Behavior Genetics 35: 397. return

31. Li MD, Cheng R, Ma JZ, Swan GE. 2003. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 98: 23-31. return

32. Hamilton AS, Lessov-Schlaggar CN, Cockburn MG, Unger JB, Cozen W, Mack TM. 2006. Gender Differences in Determinants of Smoking Initiation and Persistence in California Twins. Cancer Epidemiol Biomarkers Prev 15: 1189-97. return

33. Pergadia ML, Heath AC, Martin NG, PA. M. 2006. Genetic analyses of DSM-IV nicotine withdrawal in adult twins. Psychol Med 36: 963-72. return

34. Lessov CN, Swan GE, Ring HZ, Khroyan TV, Lerman C. 2004. Genetics and Drug Use as a Complex Phenotype. Substance Use & Misuse 39: 1515. return

35. Koopmans JR, Slutske WS, Heath AC, Neale MC, Boomsma DI. 1999. The genetics of smoking initiation and quantity smoked in Dutch adolescent and young adult twins. Behav Genet 29: 383-93. return

36. Swan GE, Carmelli D, Rosenman RH, Fabsitz RR, Christian JC. 1990. Smoking and alcohol consumption in adult male twins: genetic heritability and shared environmental influences. J Subst Abuse 2: 39-50. return

37. Swan GE, Carmelli, D., Cardon, L. R. 1996. The consumption of tobacco, alcohol, and coffee in Caucasian male twins: a multivariate genetic analysis. J Subst Abuse 8: 19-31. return

38. Swan GE, Carmelli D, Cardon LR. 1997. Heavy consumption of cigarettes, alcohol and coffee in male twins. J Stud Alcohol 58: 182-90. return

39. Vink JM, Beem AL, Posthuma D, Neale MC, Willemsen G, Kendler KS SP, Boomsma DI. 2004. Linkage analysis of smoking initiation and quantity in Dutch sibling pairs. Pharmacogenomics J 4: 274-82. return

40. True WR, Xian H, Scherrer JF, Madden PAF, Bucholz KK, et al. 1999. Common Genetic Vulnerability for Nicotine and Alcohol Dependence in Men. Arch Gen Psychiatry 56: 655-61. return

41. Broms U, Silventoinen K, Madden PA, Heath AC, Kaprio J. 2006. Genetic architecture of smoking behavior: a study of Finnish adult twins. Twins Res Hum Genet 9: 64-72. return

42. Xian H, Scherrer J, Madden P, Lyons M, Tsuang M, et al. 2003. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine & Tobacco Research 5: 245. return

43. Lessov CN, Martin NG, Statham DJ, Todorov AA, Slutske WS, et al. 2004. Defining nicotine dependence for genetic research: evidence from Australian twins. Psychol Med 34: 865-79. return

44. Tyndale RF. 2003. Genetics of alcohol and tobacco use in humans. Ann Med 35: 94-121. return

45. Hall W, Madden P, Lynskey M. 2002. The genetics of tobacco use: methods, findings and policy implications. Tob Control 11: 119-24. return

46. Swan GE, Hops H, Wilhelmsen KC, Lessov-Schlaggar CN, Cheng LS, et al. 2006. A genome-wide screen for nicotine dependence susceptibility loci. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 141B: 354-60. return

47. Ho MK, Tyndale RF. In press. Overview of the Pharmacogenomics of Cigarette Smoking. Pharmacogenomics J. return

48. Al Koudsi N, Tyndale RF. 2005. Genetic influences on smoking: a brief review. Ther Drug Monit 27: 704-9. return

49. Neville MJ, Johnstone EC, Walton RT. 2004. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23: 540-5. return

50. Hauge XY, Grandy DK, Eubanks JH, Evans GA, Civelli O, Litt M. 1991. Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 10: 527-30. return

51. Kidd KK, Morar B, Castiglione CM, Zhao H, Pakstis AJ, et al. 1998. A global survey of haplotype frequencies and linkage disequilibrium at the DRD2 locus. Hum Genet 103: 211-27. return

52. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, et al. 1999. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4: 290-6. return

53. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, et al. 1998. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 3: 256-60. return

54. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, et al. 1997. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7: 479-84. return

55. Noble EP, St Jeor ST, Ritchie T, Syndulko K, St Jeor SC, et al. 1994. D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses 42: 257-60. return

56. Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D. 1996. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 6: 73-9. return

57. Bierut LJ, Rice JP, Edenberg HJ, Goate A, Foroud T, et al. 2000. Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. Am J Med Genet 90: 299-302. return

58. Spitz MR, Shi H, Yang F, Hudmon KS, Jiang H, et al. 1998. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 90: 358-63. return

59. Johnstone EC, Yudkin P, Griffiths SE, Fuller A, Murphy M, Walton R. 2004. The dopamine D2 receptor C32806T polymorphism (DRD2 Taq1A RFLP) exhibits no association with smoking behaviour in a healthy UK population. Addict Biol 9: 221-6. return

60. Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, et al. 2005. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 5: 21-9. return

61. Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, et al. 2004. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14: 83-90. return

62. Yudkin P, Munafo M, Hey K, Roberts S, Welch S, et al. 2004. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. Bmj 328: 989-90. return

63. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, et al. 2006. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31: 231-42. return

64. Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH. 2005. Effects of dopamine D2 receptor (DRD2) and transporter (SLC6A3) polymorphisms on smoking cue-induced cigarette craving among African-American smokers. Mol Psychiatry 10: 407-14. return

65. Lerman C, Caporaso NE, Audrain J, Main D, Bowman ED, et al. 1999. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18: 14-20. return

66. Sabol SZ, Nelson ML, Fisher C, Gunzerath L, Brody CL, et al. 1999. A genetic association for cigarette smoking behavior. Health Psychol 18: 7-13. return

67. Olsson C, Anney R, Forrest S, Patton G, Coffey C, et al. 2004. Association between dependent smoking and a polymorphism in the tyrosine hydroxylase gene in a prospective population-based study of adolescent health. Behav Genet 34: 85-91. return

68. Anney RJ, Olsson CA, Lotfi-Miri M, Patton GC, Williamson R. 2004. Nicotine dependence in a prospective population-based study of adolescents: the protective role of a functional tyrosine hydroxylase polymorphism. Pharmacogenetics 14: 73-81. return

69. McKinney EF, Walton RT, Yudkin P, Fuller A, Haldar NA, et al. 2000. Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 10: 483-91. return

70. Ito H, Hamajima N, Matsuo K, Okuma K, Sato S, et al. 2003. Monoamine oxidase polymorphisms and smoking behaviour in Japanese. Pharmacogenetics 13: 73-9. return

71. Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, et al. 2005. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics 15: 393-8. return

72. Li MD, Beuten J, Ma JZ, Payne TJ, Lou XY, et al. 2005. Ethnic- and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. Hum Mol Genet 14: 1211-9. return

73. Lueders KK, Hu S, McHugh L, Myakishev MV, Sirota LA, Hamer DH. 2002. Genetic and functional analysis of single nucleotide polymorphisms in the beta2-neuronal nicotinic acetylcholine receptor gene (CHRNB2). Nicotine Tob Res 4: 115-25. return

74. Silverman MA, Neale MC, Sullivan PF, Harris-Kerr C, Wormley B, et al. 2000. Haplotypes of four novel single nucleotide polymorphisms in the nicotinic acetylcholine receptor beta2-subunit (CHRNB2) gene show no association with smoking initiation or nicotine dependence. Am J Med Genet 96: 646-53. return

75. Feng Y, Niu T, Xing H, Xu X, Chen C, et al. 2004. A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet 75: 112-21. return

76. Walters CL, Cleck JN, Kuo YC, Blendy JA. 2005. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46: 933-43. return

77. Ji SP, Zhang Y, Van Cleemput J, Jiang W, Liao M, et al. 2006. Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse. Nat Med 12: 324-9. return

78. Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, et al. 2004. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4: 184-92. return

79. do Prado-Lima PA, Chatkin JM, Taufer M, Oliveira G, Silveira E, et al. 2004. Polymorphism of 5HT2A serotonin receptor gene is implicated in smoking addiction. Am J Med Genet B Neuropsychiatr Genet 128: 90-3. return

80. Polesskaya OO, Sokolov BP. 2002. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 67: 812-22. return

81. Benowitz NL. 1993. Nicotine replacement therapy. What has been accomplished--can we do better? Drugs 45: 157-70. return

82. Schuh LM, Schuh KJ, Henningfield JE. 1996. Pharmacologic Determinants of Tobacco Dependence. Am J Ther 3: 335-41. return

83. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. 2004. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev: CD000146. return

84. Stead L, Lancaster T. 2005. Nicotine replacement therapy for smoking cessation: Cochrane systematic review. Int J Epidemiol 34: 1001-2; discussion 2, 3. return

85. Frishman WH, Mitta W, Kupersmith A, Ky T. 2006. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol Rev 14: 57-73. return

86. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. 2005. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 55: 281-99; quiz 322-3, 5. return

87. Mitrouska I, Bouloukaki I, Siafakas NM. 2006. Pharmacological approaches to smoking cessation. Pulm Pharmacol Ther. return

88. Paperwalla KN, Levin TT, Weiner J, Saravay SM. 2004. Smoking and depression. Med Clin North Am 88: 1483-94, x-xi. return

89. Quattrocki E, Baird A, Yurgelun-Todd D. 2000. Biological aspects of the link between smoking and depression. Harv Rev Psychiatry 8: 99-110. return

90. Durcan MJ, Deener G, White J, Johnston JA, Gonzales D, et al. 2002. The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clin Ther 24: 540-51. return

91. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, et al. 1999. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340: 685-91. return

92. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, et al. 2000. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 148: 33-40. return

93. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, et al. 2001. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 357: 1571-5. return

94. Argyelan M, Szabo Z, Kanyo B, Tanacs A, Kovacs Z, et al. 2005. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord 89: 115-23. return

95. Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B. 2003. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 54: 800-5. return

96. Alkondon M, Albuquerque EX. 2005. Nicotinic receptor subtypes in rat hippocampal slices are differentially sensitive to desensitization and early in vivo functional up-regulation by nicotine and to block by bupropion. J Pharmacol Exp Ther 313: 740-50. return

97. Fryer JD, Lukas RJ. 1999. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288: 88-92. return

98. Slemmer JE, Martin BR, Damaj MI. 2000. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295: 321-7. return

99. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM. 1994. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11: 133-41. return

100. Vorel SR, Liu X, Hayes RJ, Spector JA, Gardner EL. 2001. Relapse to cocaine-seeking after hippocampal theta burst stimulation. Science 292: 1175-8. return

101. Bondarev ML, Bondareva TS, Young R, Glennon RA. 2003. Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 474: 85-93. return

102. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, et al. 2004. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66: 675-82. return

103. Tyndale RF, Benowitz NL, Sellers E, Swan GE, Wong SSY. 2006. CYP2A6 gene amplification enhances nicotine metabolism increasing smoking. Submitted. return

104. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. 2002. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. Jama 288: 468-74. return

105. Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. 2004. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction 99: 1206-18. return

106. Gold PB, Rubey RN, Harvey RT. 2002. Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care. Am J Addict 11: 315-31. return

107. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, et al. 2001. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 135: 423-33. return

108. Hughes J, Stead L, Lancaster T. 2004. Antidepressants for smoking cessation. Cochrane Database Syst Rev: CD000031. return

109. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, et al. 1997. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337: 1195-202. return

110. Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, et al. 2001. Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. Clin Ther 23: 744-52. return

111. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, et al. 2003. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 163: 2337-44. return

112. Tonnesen P, Tonstad S, Hjalmarson A, Lebargy F, Van Spiegel PI, et al. 2003. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 254: 184-92. return

113. Zellweger JP, Boelcskei PL, Carrozzi L, Sepper R, Sweet R, Hider AZ. 2005. Bupropion SR vs placebo for smoking cessation in health care professionals. Am J Health Behav 29: 240-9. return

114. Tashkin D, Kanner RE, Bailey WC, Buist AS, Anderson PJ, et al. 1997. A multicenter evaluation of the effects of bupropion hydroxhloride sustained release tablets (BUP SR) versus placebo in a population of smokers with chronic obstructive pulmonary disease (COPD). Presented at Proceedings of the 7 Annual Meeting of the Society for Research on Nicotine and Tobacco, Seattle, Washington. return

115. Boshier A, Wilton LV, Shakir SA. 2003. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol 59: 767-73. return

116. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, et al. 2005. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474-7. return

117. Papke RL, Heinemann SF. 1994. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit. Mol Pharmacol 45: 142-9. return

118. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, et al. 2006. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. Jama 296: 47-55. return

119. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, et al. 2006. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Jama 296: 56-63. return

120. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. 2000. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 22: 809-19. return

121. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, et al. 2000. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 65: 191-8. return

122. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, et al. 2005. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 78: 456-67. return

123. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, et al. 2005. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 35: 2031-40. return

124. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P. 2002. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13: 451-63. return

125. Anthenelli RM, Despres JP. 2004. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US trial (smoking cessation in smokers motivated to quit). Presented at American College of Cardiology 53rd Annual Scientific Session, Rapid News Summaries, New Orleans, LA. return

126. Anthenelli RM. 2005. Rimonabant in smoking abstinence: the STRATUS-program. Presented at Proceedings of the 11 Annual Meeting of the Society for Research on Nicotine and Tobacco, Prague, Czech Republic. return

127. Benowitz NL, Jacob P, 3rd. 1994. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 56: 483-93. return

128. Messina ES, Tyndale RF, Sellers EM. 1997. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282: 1608-14. return

129. Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, et al. 2004. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 76: 519-27. return

130. Xu C, Rao YS, Xu B, Hoffmann E, Jones J, et al. 2002. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun 290: 318-24. return

131. Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, et al. 2004. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur J Pharm Sci 22: 419-25. return

132. Yoshida R, Nakajima M, Watanabe Y, Kwon JT, Yokoi T. 2002. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 54: 511-7. return

133. Henningfield JE, Goldberg SR. 1988. Pharmacologic determinants of tobacco self-administration by humans. Pharmacol Biochem Behav 30: 221-6. return

134. Russell MA, Feyerabend C. 1978. Cigarette smoking: a dependence on high-nicotine boli. Drug Metab Rev 8: 29-57. return

135. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. 2006. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry. return

136. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, et al. 2000. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 58: 747-55. return

137. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. 2004. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14: 615-26. return

138. Gu DF, Hinks LJ, Morton NE, Day IN. 2000. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 64: 383-90. return

139. Minematsu N, Nakamura H, Furuuchi M, Nakajima T, Takahashi S, et al. 2006. Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms. Eur Respir J 27: 289-92. return

140. Draper AJ, Madan A, Parkinson A. 1997. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341: 47-61. return

141. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, Trager WF. 1997. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25: 1407-15. return

142. Maenpaa J, Juvonen R, Raunio H, Rautio A, Pelkonen O. 1994. Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochem Pharmacol 48: 1363-9. return

143. Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. 2001. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 29: 897-902. return

144. Tyndale RF, Li Y, Kaplan HL, Seller EM. 1999. Inhibition of nicotine's metabolism: a potential new treatment for tobacco dependence [abstract]. Clin Pharmacol Ther 65: 145. return

145. Sellers EM, Kaplan HL, Tyndale RF. 2000. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 68: 35-43. return

NEWS SEARCH CONTENTS MEDITORIAL ASK DISCUSS REGISTER HELP HOME